Biotechnology Research Center, Student Research Committee and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Research Center for Pharmaceutical Nanotechnology, and Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
J Control Release. 2020 Apr 10;320:265-282. doi: 10.1016/j.jconrel.2020.01.028. Epub 2020 Jan 18.
The novel polymeric particulate systems show high potential in their clinical effectiveness. Nevertheless, many of the drug delivery systems developed in the research laboratories have not found their way to clinics. The lack of therapeutic efficacy and safety, due to the use of some materials unapproved by the FDA, seems to be an important reason behind the unsuitability of the developed polymeric systems for the clinical application. Through specific design, choice of proper approach and excipients, the zero order linear release is highly achievable. The aim of this review was to explain the challenges associated with formulation development for several therapeutic agents in polymeric particulate system by scientific evidences. Growing interest in biotechnology and application of therapeutic proteins and peptides in various pathogenic disorders caused our special focus on their quality and preparation challenges. In this review, all formulation development issues i.e. choice of material, the amount of their use and regulatory policies were discussed. In the rest, other formulation development parameters such as effect of particle size, pH, drug loading as well as production method difficulties, dosage form qualities and route of administration to reach high quality particles were reviewed. Generally, this review tried to address an overview on how to solve the difficulties in the path of development of the polymeric particles for the pharmaceutical purposes.
新型聚合颗粒系统在临床效果方面显示出巨大潜力。然而,许多在研究实验室开发的药物输送系统尚未进入临床应用。由于使用了一些未经 FDA 批准的材料,导致治疗效果和安全性缺乏,这似乎是开发的聚合系统不适合临床应用的一个重要原因。通过特定的设计、适当方法和赋形剂的选择,可以实现零级线性释放。本综述的目的是通过科学证据解释与聚合颗粒系统中几种治疗剂制剂开发相关的挑战。人们对生物技术的兴趣日益浓厚,以及治疗性蛋白质和肽在各种病理疾病中的应用,使我们特别关注它们的质量和制剂开发方面的挑战。在这篇综述中,我们讨论了所有制剂开发问题,例如材料的选择、使用量和监管政策。在其余部分,还回顾了其他制剂开发参数,例如颗粒大小、pH 值、药物载药量以及生产方法困难、剂型质量和给药途径对获得高质量颗粒的影响。总的来说,本综述试图概述如何解决制药用途的聚合颗粒开发过程中的困难。